134 related articles for article (PubMed ID: 38564927)
41. Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.
Richardson NH; Althouse SK; Ashkar R; Cary C; Masterson T; Foster RS; Einhorn LH; Adra N
Clin Genitourin Cancer; 2023 Aug; 21(4):467-474. PubMed ID: 37088659
[TBL] [Abstract][Full Text] [Related]
42. Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors.
Green DB; La Rosa FG; Craig PG; Khani F; Lam ET
Korean J Radiol; 2021 Oct; 22(10):1650-1657. PubMed ID: 34402242
[TBL] [Abstract][Full Text] [Related]
43. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
44. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
45. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.
Ko JJ; Bernard B; Tran B; Li H; Asif T; Stukalin I; Lee M; Day D; Alimohamed N; Sweeney CJ; Bedard PL; Heng DY
J Clin Oncol; 2016 Mar; 34(7):714-20. PubMed ID: 26786931
[TBL] [Abstract][Full Text] [Related]
46. Outcome of testicular non-seminomatous germ cell tumours: report from a tertiary cancer centre in eastern India.
Biswas B; Dabkara D; Ganguly S; Ghosh J; Gupta S; Sen S; Chatterjee M; Basu A; Mukherjee S
Ecancermedicalscience; 2021; 15():1204. PubMed ID: 33889213
[TBL] [Abstract][Full Text] [Related]
47. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Derquin F; Floquet A; Hardy-Bessard AC; Edeline J; Lotz JP; Alexandre J; Pautier P; Angeles MA; Delanoy N; Lefeuvre-Plesse C; Cancel M; Treilleux I; Augereau P; Lavoue V; Kalbacher E; Berton Rigaud D; Selle F; Nadeau C; Gantzer J; Joly F; Guillemet C; Pomel C; Favier L; Abdeddaim C; Venat-Bouvet L; Provansal M; Fabbro M; Kaminsky MC; Lortholary A; Lecuru F; Coquard IR; de La Motte Rouge T
Gynecol Oncol; 2020 Sep; 158(3):666-672. PubMed ID: 32624235
[TBL] [Abstract][Full Text] [Related]
48. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
49. CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.
Fankhauser CD; Roth L; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Moch H; Bode PK; Beyer J; Hermanns T
BMC Cancer; 2019 Aug; 19(1):802. PubMed ID: 31412792
[TBL] [Abstract][Full Text] [Related]
50. Patterns of supradiaphragmatic metastases in testicular germ cell tumours.
Wood A; Robson N; Tung K; Mead G
Clin Radiol; 1996 Apr; 51(4):273-6. PubMed ID: 8617040
[TBL] [Abstract][Full Text] [Related]
51. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
52. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
[TBL] [Abstract][Full Text] [Related]
53. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.
Spratt DE; Suresh K; Osawa T; Schipper M; Jackson WC; Abugharib A; Lebastchi A; Smith D; Montgomery JS; Palapattu GS; Priya Kunju L; Wu A; Lew M; Tomlins SA; Chinnaiyan AM; Weizer AZ; Hafez KS; Kaffenberger SD; Udager A; Mehra R
Med Oncol; 2018 Jan; 35(3):21. PubMed ID: 29387987
[TBL] [Abstract][Full Text] [Related]
54. Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.
Majewski M; Paffenholz P; Ruf C; Che Y; Seidel C; Heinzelbecker J; Schmelz HU; Matthies C; Albers P; Bokemeyer C; Heidenreich A; Pichler M; Nestler T;
Cancer Med; 2023 Aug; 12(16):16829-16836. PubMed ID: 37392170
[TBL] [Abstract][Full Text] [Related]
55. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
56. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
57. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer.
Geldart TR; Simmonds PD; Mead GM
BJU Int; 2002 Sep; 90(4):451-5. PubMed ID: 12175407
[TBL] [Abstract][Full Text] [Related]
58. Pitfalls in the interpretation of specimens from patients with testicular tumours, with an emphasis on variant morphologies.
Ulbright TM
Pathology; 2018 Jan; 50(1):88-99. PubMed ID: 29129333
[TBL] [Abstract][Full Text] [Related]
59. Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17.
Zhou Y; Rothrock A; Murugan P; Li F; Bu L
Exp Mol Pathol; 2022 Jun; 126():104761. PubMed ID: 35390309
[TBL] [Abstract][Full Text] [Related]
60. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
